

Trend Macrolytics, LLC Donald Luskin, Chief Investment Officer Thomas Demas, Managing Director Michael Warren, Energy Strategist

#### Data Insights: Covid-2019 Monitor

Wednesday, February 2, 2022

#### The global scorecard



Cases: 7-day average and daily Deaths: Daily

#### For more information contact us:

Donald Luskin: 214 550 2121 <u>don@trendmacro.com</u> Thomas Demas: 704 552 3625 <u>tdemas@trendmacro.com</u>

Copyright 2022 Trend Macrolytics LLC. All rights reserved. This document is not to be forwarded to individuals or organizations not authorized by Trend Macrolytics LLC to receive it. For information purposes only; not to be deemed to be recommendations for buying or selling specific securities or to constitute personalized investment advice. Derived from sources deemed to be reliable, but no warranty is made as to accuracy.



Source: Johns Hopkins, Dept. of Health and Human Services, CDC, TrendMacro calculations

| Kolling                         | out th     | ie vacc   | ines in                   | the US                           | S and t     | he wor     | ld   |                  |             |                             |             |        |
|---------------------------------|------------|---|---------------------------|----------------------------------|-------------|------------|--|------------------|-------------|-----------------------------|-------------|--------|
| Administered Cum                |            | Ilative   |                           |                                  |             |            | То   | day              | Immunity    | Full                        | Partial     |        |
| Doses                           |            | 55  | 553,536,035               |                                  |             |            |  | +0.585           | million     | US                          | 63.6%       | 75.4%  |
| Boosters                        |            | 89,472,570  |                           |                                  |             |            |  | +0.286           | million     | UK                          | 71.0%       | 76.8%  |
|                                 |            | One dose  |                           | % Pop Imn                        |             | nune       | % рор  | New immune today |             | France                      | 76.4%       | 79.8%  |
| Total population                |            | 25  | 57,688,183                | 77%                              | 218,015,541 |            | 65%  | +0.135 million   |             | Spain                       | 81.9%       | 87.5%  |
| Age 12 to 1                     | 7          |   | 16,971,793                |                                  |             | 14,338,842 | 57%  | +0.016 million   |             | Germany                     | 73.4%       | 75.2%  |
| Age 18 to 64                    |            | 173,923,922   |                           | 85%                              | 85% 1       |            | 72%  | +0.063 million   |             | ltaly                       | 76.5%       | 83.2%  |
| Age 65 and over                 |            | Ę   | 57,932,493                |                                  |             | 50,115,869 | 91%  | +0.006 million   |             | Australia                   | 78.4%       | 84.2%  |
| l&l                             |            |   |                           |                                  |             |            |  |                  |             | Israel                      | 65.6%       | 72.0%  |
| Moderna<br>38%<br>Pfizer<br>59% |            | -   |                           |                                  |             |            |  |                  |             | Canada                      | 79.3%       | 85.2%  |
|                                 |            | State<br>At least partial immunity<br>as % population |                           | Best                             | t           |            |  |                  |             | Japan                       | 79.2%       | 80.4%  |
|                                 |            |   |                           | Middle                           |             |            |  |                  |             | Africa                      | 10.9%       | 16.1%  |
|                                 |            |   |                           |                                  |             |            |  |                  |             | India                       | 51.3%       | 67.8%  |
|                                 |            |   |                           |                                  |             |            |  |                  |             | Brazil                      | 70.1%       | 79.7%  |
|                                 |            |   |                           | Wors                             | st          |            |  |                  |             | China<br>Global data differ | 85.0%       | 87.7%  |
|                                 |            | as % population                                       |                           |                                  |             | W/I        |  | As of Feb 1      |             |                             |             | , anng |
| 67.9%                           |            |   | 0 00000                   |                                  |             |            |  | 73 01100 1       |             |                             |             |        |
| 58.4%                           |            |   |                           |                                  |             | 70.4%      |  |                  |             |                             | 88.6%       |        |
| ſ                               | W/A        | ID  | МТ                        | ND                               | MN          | 03.0%      | MI   | 1                | NY          | VT                          | 77.0%<br>NH |        |
|                                 | 78.8%      | 59.6%   | 63.8%                     | 64.0%                            | 73.6%       | 75.5%      | 65.2%  |                  | 87.6%       | Q2.2%                       | 95.0%       |        |
|                                 | 70.0%      | 52.3%   | 55.2%                     | 54.0%                            | 67.1%       | 66.3%      | 58.2%  |                  | 7/ 2%       | 79.1%                       | 68.8%       |        |
|                                 | 0.1 /0     | NV  | WY                        | SD                               | Ι <u>Α</u>  | IN         | 0H   | PA               | N.I         | MA                          | 00.070      |        |
|                                 | 76.2%      | 73.0%   | 57.3%                     | 73.9%                            | 66.7%       | 60.0%      | 62.4%  | 82.1%            | 87.6%       | 95.0%                       |             |        |
|                                 | 67.9%      | 58.5%   | 49.9%                     | 58.9%                            | 60.4%       | 53.3%      | 56.8%  | 65.8%            | 72.8%       | 76.5%                       |             |        |
|                                 | CA         | UT  | CO                        | NE                               | MO          | KY         | WV   | VA               | MD          | CT                          | RI          |        |
|                                 | 80.4%      | 69.8%   | 77.5%                     | 68.7%                            | 64.7%       | 64.7%      | 63.6%  | 83.2%            | 83.7%       | 92.6%                       | 94.7%       |        |
|                                 | 69.1%      | 60.7%   | 68.3%                     | 61.6%                            | 54.4%       | 55.7%      | 56.2%  | 70.6%            | 72.7%       | 76.6%                       | 79.1%       |        |
| -                               |            | AZ  | NM                        | KS                               | AR          | TN         | NC   | SC               | DC          | DE                          |             |        |
|                                 |            | 70.2%   | 84.6%                     | 72.5%                            | 65.0%       | 60.7%      | 80.9%  | 65.7%            | 93.3%       | 80.5%                       |             |        |
|                                 |            | 58.9%   | 68.4%                     | 59.1%                            | 52.7%       | 52.8%      | 58.5%  | 55.0%            | 70.1%       | 66.3%                       |             |        |
|                                 |            |   |                           | OK                               | LA          | MS         | AL   | GA               |             |                             |             |        |
|                                 |            |   |                           | 69.2%                            | 59.5%       | 58.1%      | 61.2%  | 63.7%            |             |                             |             |        |
| HI                              |            |   | 55.2%                     | 51.8%                            | 50.1%       | 49.5%      | 52.9%  |                  |             |                             |             |        |
| 85.0%                           |            |   | TX                        |                                  |             |            |  | FL               |             | PR                          |             |        |
| 75.9%                           |            |   |                           | 69.8%                            |             |            |  |                  | 77.2%       |                             | 93.2%       |        |
|                                 |            |   | 58.9%                     | l                                |             |            |  | 65.1%            | l l         | 79.5%                       |             |        |
| <b>T</b> 1 1                    |            |   | •                         |                                  |             |            |  |                  |             |                             |             |        |
| The demog                       | raphics of | US vaccinat   | tion                      |                                  |             |            |  |                  |             |                             |             |        |
| 70%65_5% of fomoloc immunized   |            |   | 60.9% of whites immunized |                                  |             | 100%       | $\frac{12.9\%}{12.9\%}$ of age <12 immunized |                  |             |                             |             |        |
| 60% - 61.2% of mates            |            |   | Zeu                       | 70% - 51.1% of African Americana |             |            |  | 90% -            | 5/ 1% 12-15 |                             |             |        |
|                                 |            |   | C00/                      | cov 64.8% of Hispanics           |             |            |  | 59.7% 16-14      |             |                             |             |        |
| 50%                             |            |   | 60%                       | 76.0% of Asians                  |             |            | 70% -  | 60.8% 18-24      |             |                             |             |        |
| 100/                            |            |   |                           | 50%                              |             |            |  | 60% -            | 64.7% 15-39 |                             |             |        |
| 40%                             |            |   | 40%                       |                                  |             |            | 50%  | 72.8% 40-49      |             |                             |             |        |
| 30%                             |            |   |                           |                                  |             |            | 100/   | 79.5% 50-6       |             |                             |             |        |
|                                 |            |   |                           | 30%                              |             | /          |  | 40%              | 90.7% 65-7  | 4//                         |             |        |
| 20% +                           |            |   | 20%                       | -  -  -  -  -  -  -  -  -  -     |             |            | 30% -  | 85.1% 75+1       |             |                             |             |        |
| 10%                             |            |   |                           | 100                              |             |            |  | 20% -            |             |                             |             |        |
|                                 |            |   |                           | 10%                              |             |            |  | 10% -            |             |                             |             |        |

#### .... ....

Source: <u>CDC</u>, <u>CDC</u>, <u>Our World in Data</u>, TrendMacro calculations -2167292 21612921 612921 612921 612921 612921 612921

216226 216 201 221 221 221 221 221 221 221 221

![](_page_3_Figure_0.jpeg)

![](_page_3_Figure_1.jpeg)

![](_page_3_Figure_2.jpeg)

![](_page_3_Figure_3.jpeg)

![](_page_3_Figure_4.jpeg)

![](_page_3_Figure_5.jpeg)

![](_page_3_Figure_6.jpeg)

![](_page_3_Figure_7.jpeg)

![](_page_3_Figure_8.jpeg)

![](_page_3_Figure_9.jpeg)

Source: Johns Hopkins, Covid Act Now, TrendMacro calculations

![](_page_4_Figure_0.jpeg)

Source: Distributions <u>CDC</u>, Comorbidities <u>CDC</u>, TrendMacro calculations

### Recommended reading

#### Covid's New Divide: Risk Takers vs. the Risk Averse

Jason Horowitz *New York Times* January 31, 2022

#### U.S. Has Far Higher Covid Death Rate Than Other Wealthy Countries Benjamin Mueller and Eleanor Lutz *New York Times*

*New York Times* February 1, 2022

#### <u>Covid and the 'Hygiene Hypothesis'</u> Eran Bendavid *Wall Street Journal* February 1, 2022

#### Powerful Immune Cells Able to Recognize Omicron Variant, Study Indicates Bloomberg February 1, 2022

<u>Time to Accept Covid and Move On?</u> *Monmouth University* January 31, 2022

<u>Ivermectin shows 'antiviral effect' against COVID,</u> <u>Japanese company says</u> *Reuters* January 31, 2022

# Meme of the day

![](_page_5_Picture_10.jpeg)

Source: Our beloved clients, Power Line blog "The Week in Pictures" and CTUP

# Australians watching the the UK remove all mask mandates

![](_page_6_Figure_0.jpeg)

# The coronavirus <u>case</u> accelerometer... tracking the world's infection curves *Share of infected population from first day with 100 confirmed cases, log scale*

![](_page_7_Figure_0.jpeg)

# The coronavirus <u>mortality</u> accelerometer ... tracking the world's fatality curves *Share of deceased population from day of first fatality, log scale*

Source: Johns Hopkins, TrendMacro calculations

![](_page_8_Figure_0.jpeg)

Requirement to <u>Open Up America Again</u>: 14-day "downward trajectory" in new cases *14-day moving average, last 14 days Most recent value displayed* • High • Low Downward trajectory Five best Upward trajectory Five worst

![](_page_9_Figure_1.jpeg)

Source: Johns Hopkins, TrendMacro calculations

Alt requirement to <u>Open Up America Again</u>: 14-day "downward trajectory" in pos tests *14-day moving average, last 14 days Most recent value displayed* • High • Low Downward trajectory Five best Upward trajectory Five worst

![](_page_10_Figure_1.jpeg)

Source: Covid Act Now, TrendMacro calculations

From Ground Zero to the Rio Grande

Cases: 7-day average and daily Deaths: Daily

![](_page_11_Figure_2.jpeg)

Source: Johns Hopkins, TrendMacro calculations

![](_page_12_Figure_0.jpeg)

Source: Johns Hopkins, TrendMacro calculations

![](_page_13_Figure_0.jpeg)

Patient zero... and then everyone else

Cases: 7-day average and daily Deaths: Daily

Source: Johns Hopkins, TrendMacro calculations

Impact in the largest economies Cases: 7-day average and daily Deaths: Daily

![](_page_14_Figure_1.jpeg)

Impact in The Anglosphere Cases: 7-day average and daily Deaths: Daily 250,000 18% United Kingdom As of Feb 1 16% 200,000 2632.43 bp of population infected 14% Daily new cases and deaths 23.62 bp of population fatalities 17,544,380 cases cumulative 12% +56,578 cases today 40.5 median population age 150,000 99.3% Omicron variant share 10% Cume fatality rate 0.90% 71.0% total population immunized 8% 100,000 2-week fatality rate 0.25% 6% 157,404 deaths cumulative 4% 50,000 +1,123 deaths today 2% 0% Mar '20 Nov '20 Sep '21 Jan '22 Jan '20 May '20 Jul '20 Sep '20 Jan '21 Mar '21 May '21 Jul '21 Nov '21 70,000 10.0% Canada 9.0% 60,000 3,066,278 cases cumulative 809.16 bp of population infected +10,697 cases today 8.0% 8.98 bp of population fatalities Daily new cases and deaths 50,000 7.0% 40.8 median population age Cume fatality rate 1.11% 6.0% Jase 40,000 96.4% Omicron variant share 79.3% total population immunized 5.0% 30,000 2-week fatality rate 0.41% 4.0% 3.0% 20,000 34,032 deaths cumulative +162 deaths today 2.0% 10,000 1.0% 0.0% Jan '20 Mar '20 May '20 Jul '20 Sep '20 Nov '20 Jan '21 Mar '21 May '21 Jul '21 Sep '21 Nov '21 Jan '22 200,000 4.5% 180,000 Australia 4.0% 2,620,532 cases cumulative 947.20 bp of population infected 160,000 +40,146 cases today 3.5% 🙀 1 bp of population fatalities 40,000 120,000 37.9 median population age 92.8% Omicron variant share 2.5% Cume fatality rate 0.15% ¥00,000 78.4% total population immunized 2.0% 2-week fatality rate 0.08% 1000,08 € 1.5% 3.905 deaths cumulative 1.0% 40,000 +70 deaths today 0.5% 20,000 0.0% Nov '21 Jan '20 Mar '20 May '20 Jul '20 Sep '20 Nov '20 Jan '21 Mar '21 May '21 Jul '21 Sep '21 Jan '22

![](_page_15_Figure_1.jpeg)

![](_page_16_Figure_0.jpeg)

Impact in other hot-spots Cases: 7-day average and daily Deaths: Daily

![](_page_17_Figure_1.jpeg)

Impact in the BRICs ex-China Cases: 7-day average and daily Deaths: Daily

![](_page_18_Figure_1.jpeg)

120,000 Israel As of Feb 1 2,966,444 cases cumulative 100,000 3339.09 bp of population infected +65,875 cases today Daily new cases and deaths 90,000 40,000 70,000 70,000 10.05 bp of population fatalities 30.2 median population age Cume fatality rate 0.30% 96.5% Omicron variant share 2-week fatality rate 0.12% 65.6% total population immunized 8,926 deaths cumulative +121 deaths today 20,000 May '20 Mar '21 Jan '20 Mar '20 Jul '20 Sep '20 Nov '20 Jan '21 May '21 Jul '21 Sep '21 Nov '21 60,000 Iran 6,408,244 cases cumulative 50,000 +35,070 cases today 732.10 bp of population infected 15.14 bp of population fatalities Cume fatality rate 2.07% Daily new cases and deaths 40,000 30.3 median population age 2-week fatality rate 1.42% 63 7% total population immunized 30,000 132,504 deaths cumulative +50 deaths today 20,000 10,000 Jan '20 Mar '20 May '20 Sep '20 Jul '21 Jul '20 Nov '20 Jan '21 Mar '21 May '21 Sep '21 Nov '21 70,000 Africa (52 nations) 60,000 12,265,136 cases cumulative

## Impact in the Middle East and Africa

Cases: 7-day average and daily Deaths: Daily

2%

2%

1%

1%

1%

1%

![](_page_19_Figure_3.jpeg)

![](_page_20_Figure_0.jpeg)

![](_page_20_Figure_1.jpeg)

Source: Johns Hopkins, TrendMacro calculations